Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Cited by (1,093)

Items 301–400 of 1,093

1. Review of hemoglobin A1c in the management of diabetes
   Emily J. Gallagher, Derek Le Roith, Zachary T. Bloomgarden · 2009 · Journal of Diabetes
2. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
   H.‐H. Parving, Barry Morton Brenner, John J.V. McMurray, Dick de Zeeuw, Steven M. Haffner, Scott David Solomon, Nish Chaturvedi, Mathieu M. Ghadanfar, Nicole Weissbach, Z. Xiang et al. · 2009 · Nephrology Dialysis Transplantation
3. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
   John J.V. McMurray, Hertzel C. Gerstein, Rury R. Holman, Marc Alan Pfeffer · 2014 · The Lancet Diabetes & Endocrinology
4. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
   American Diabetes Association · 2017 · Diabetes Care
5. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
   Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Cefalu, William T., Januzzi, James L., Kalyani, Rita Rastogi, Kosiborod, Mikhail, Magwire, Melissa L., Morris, Pamela B. et al. · 2018 · Journal of the American College of Cardiology
6. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary
   Sinclair, Alan J., Paolisso, Giuseppe, Castro, Marta, Bourdel-Marchasson, Isabelle, Gadsby, Roger, Rodriguez Mañas, Leocadio · 2011 · Diabetes & Metabolism
7. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
   Ma, Xiaoxuan, Liu, Zhenghong, Ilyas, Iqra, Little, Peter J., Kamato, Danielle, Sahebka, Amirhossein, Chen, Zhengfang, Luo, Sihui, Zheng, Xueying, Weng, Jianping et al. · 2021 · International Journal of Biological Sciences
8. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
   Sanjoy Ketan Paul, Kerenaftali Klein, Brian Larsen Thorsted, Michael Lyng Wolden, Kamlesh K. Khunti · 2015 · Cardiovascular Diabetology
9. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
   Vaccaro, Olga, Masulli, Maria, Nicolucci, Antonio, Bonora, Enzo, Del Prato, Stefano, Maggioni, Aldo P, Rivellese, Angela A, Squatrito, Sebastiano, Giorda, Carlo B, Sesti, Giorgio et al. · 2017 · The Lancet Diabetes & Endocrinology
10. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
11. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
    Muhammad A Abdul‐Ghani, Stefano Del Prato, ROBERT J. CHILTON, Ralph Anthony DeFronzo · 2016 · Diabetes Care
12. Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    Eleuterio Ferrannini, Vivian Andrew Fonseca, Bernard Zinman, David Richard Matthews, Bo Åhrén, Stuart Byiers, Qin Shao, Sylvie Dejager · 2008 · Diabetes Obesity and Metabolism
13. The role of epigenetics in the pathology of diabetic complications
    Louisa M. Villeneuve, Rama D Natarajan · 2010 · American Journal of Physiology-Renal Physiology
14. 11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
    American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
15. Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
    Per‐Henrik Groop, Mark Emmanuel Cooper, Vlado Perkovic, Angela Emser, Hans‐Juergen Woerle, Maximilian von Eynatten · 2013 · Diabetes Care
16. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
    Richard E. Gilbert, Henry Krum · 2015 · The Lancet
17. Diabetes and atherosclerosis: is there a role for hyperglycemia?
    Alan Chait, Karin Bornfeldt · 2008 · Journal of Lipid Research
18. Cardiovascular Complications of Diabetic Kidney Disease
    Ragnar Pálsson, Uptal D. Patel · 2014 · Advances in Chronic Kidney Disease
19. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
    Bianca Hemmingsen, Søren Søgaard Lund, Christian Nyfeldt Gluud, Allan Arthur Vaag, Thomas Almdal, Jørn Wetterslev · 2015 · Cochrane Database of Systematic Reviews · Retracted
20. Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study
    Sarah R. Preis, Michael J. Pencina, Shih‐Jen Hwang, Ralph B. D’Agostino, Peter J. Savage, Daniel A Levy, Caroline S. Fox · 2009 · Circulation
21. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana M. Isaacs, Eric L. Johnson et al. · 2022 · Diabetes Care
22. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis
    Kahn, Richard, Alperin, Peter, Eddy, David, Borch-Johnsen, Knut, Buse, John, Feigelman, Justin, Gregg, Edward, Holman, Rury R, Kirkman, M Sue, Stern, Michael et al. · 2010 · The Lancet
23. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus
    Keiichi Torimoto, Yosuke Okada, Hiroko Mori, Yoshiya Tanaka · 2013 · Cardiovascular Diabetology
24. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaëla Diamant, Ele Ferrannini, Michael Albrecht Nauck, Anne L. Peters, Απόστολος Τσάπας, Richard C. Wender, David Richard Matthews · 2012 · Diabetes Spectrum
25. Cardiomyopathy in obesity, insulin resistance and diabetes
    Michinari Nakamura, Junichi Sadoshima · 2019 · The Journal of Physiology
26. Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes
    John L. Sievenpiper, Cyril W.C. Kendall, A. Esfahani, Josephine Wong, Amanda J. Carleton, H. Y. Jiang, Richard Paul Bazinet, Edward Vidgen, David J.A. Jenkins · 2009 · Diabetologia
27. The Diabetes Mellitus Medication Choice Decision Aid
    Rebecca J. Mullan, Víctor M. Montori, Nilay D. Shah, Teresa J. H. Christianson, Sandra C. Bryant, Gordon Henry Guyatt, Lilisbeth Perestelo‐Pérez, Robert J. Stroebel, Barbara P. Yawn, Victor P. Yapuncich et al. · 2009 · Archives of Internal Medicine
28. Macrovascular Complications in Patients with Diabetes and Prediabetes
    Dou Huang, Marwan M. Refaat, Kamel Mohammedi, Amin Jayyousi, Jassim M. S. Al Suwaidi, Charbel Abi Khalil · 2017 · BioMed Research International
29. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study
    Lu, Jingyi, Wang, Chunfang, Shen, Yun, Chen, Lei, Zhang, Lei, Cai, Jinghao, Lu, Wei, Zhu, Wei, Hu, Gang, Xia, Tian et al. · 2021 · Diabetes Care
30. Evaluating All Potential Oral Complications of Diabetes Mellitus
    Martijn J. L. Verhulst, Bruno G. Loos, Victor E. A. Gerdes, Wijnand J. Teeuw · 2019 · Frontiers in Endocrinology
31. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
    Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay et al. · 2023 · Diabetes Care
32. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global <scp>HAT</scp> study
    Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H. et al. · 2016 · Diabetes Obesity and Metabolism
33. Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
    Kovatchev, Boris P. · 2017 · Nature Reviews Endocrinology
34. Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications
    Xiaohui Zhuo, Ping Zhang, Thomas J. Hoerger · 2013 · American Journal of Preventive Medicine
35. 6. Glycemic Targets
    American Diabetes Association · 2016 · Diabetes Care
36. Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney Disease
    Sabin Shurraw · 2011 · Archives of Internal Medicine
37. Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis
    Κωνσταντίνος Τζιόμαλος, Vasilios Gabriel Athyros · 2015 · The Review of Diabetic Studies
38. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
    Nancy A. Thornberry, Baptist Gallwitz · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
39. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
    Bastiaan E. de Galan, Vlado Perkovic, Toshiharu Ninomiya, Avinesh Pillai, Anushka A Patel, Alan Cass, Bruce Charles Neal, Neil R Poulter, Stephen B. Harrap, Carl-Erik Mogensen et al. · 2009 · Journal of the American Society of Nephrology
40. Diabetes mellitus and cognitive impairments
    Elham Saedi, Mohammad Reza Gheini, Firoozeh Faiz, Mohammad Ali Arami · 2016 · World Journal of Diabetes
41. Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
    Zahir H. Alshehry, Piyushkumar A. Mundra, Christopher K. Barlow, Natalie A. Mellett, Gerard Wong, Malcolm John McConville, John R. Simes, Andrew Tonkin, DAVID R. SULLIVAN, Elizabeth Helen Barnes et al. · 2016 · Circulation
42. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
    Molitch, Mark E., Adler, Amanda I., Flyvbjerg, Allan, Nelson, Robert G., So, Wing-Yee, Wanner, Christoph, Kasiske, Bertram L., Wheeler, David C., de Zeeuw, Dick, Mogensen, Carl E. · 2015 · Kidney International
43. Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
    Boussageon, Rémy, Supper, Irène, Bejan-Angoulvant, Theodora, Kellou, Nadir, Cucherat, Michel, Boissel, Jean-Pierre, Kassai, Behrouz, Moreau, Alain, Gueyffier, François, Cornu, Catherine · 2012 · PLoS Medicine
44. UKPDS and the legacy effect
    Chalmers, John, Cooper, Mark E. · 2008 · New England Journal of Medicine
45. Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
    Chan‐Young Jung, Tae‐Hyun Yoo · 2022 · Diabetes & Metabolism Journal
46. A diabetes-predictive amino acid score and future cardiovascular disease
    Martin Magnusson, Gregory D. Lewis, Ulrika Ericson, Marju Orho‐Melander, Bo Hedblad, Gunnar Engström, Gerd Östling, Clary B. Clish, Thomas J. Wang, Robert Edgardo Gerszten et al. · 2012 · European Heart Journal
47. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
    Fruchart, Jean-Charles, Sacks, Frank M, Hermans, Michel P, Assmann, Gerd, Brown, W Virgil, Ceska, Richard, Chapman, M John, Dodson, Paul M, Fioretto, Paola, Ginsberg, Henry N et al. · 2008 · Diabetes and Vascular Disease Research
48. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction
    Chaitman, Bernard R., Hardison, Regina M., Adler, Dale, Gebhart, Suzanne, Grogan, Mary, Ocampo, Salvador, Sopko, George, Ramires, Jose A., Schneider, David, Frye, Robert L. et al. · 2009 · Circulation
49. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
    Mikhail Kosiborod, Marília Brito Gomes, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Marina Vladimirovna Shestakova, Hirotaka Watada, Iichiro Shimomura, Hungta Chen, Javier Cid‐Ruzafa et al. · 2018 · Cardiovascular Diabetology
50. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
51. Six ‘biases’ against patients and carers in evidence-based medicine
    Trisha Greenhalgh, Rosamund Snow, Sara Ryan, Siân Rees, Helen Salisbury · 2015 · BMC Medicine
52. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
53. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
    Ele Ferrannini, Ralph Anthony DeFronzo · 2015 · European Heart Journal
54. Hypoglycemia: The neglected complication
    Kalra, Sanjay, Mukherjee, Jagat Jyoti, Venkataraman, Subramanium, Bantwal, Ganapathi, Shaikh, Shehla, Saboo, Banshi, Das, Ashok Kumar, Ramachandran, Ambady · 2013 · Indian Journal of Endocrinology and Metabolism
55. Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes
    Sophia Zoungas, Bastiaan E. de Galan, Toshiharu Ninomiya, Diederick E. Grobbee, Pavel Hamet, Simon R. Heller, Stephen W MacMahon, Michel Marre, Bruce Charles Neal, Anushka A Patel et al. · 2009 · Diabetes Care
56. Gene Silencing of the Mitochondrial Adaptor p66 Shc Suppresses Vascular Hyperglycemic Memory in Diabetes
    Francesco Paneni, Pavani Mocharla, Alexander T. Akhmedov, Sarah Costantino, Elena Osto, Massimo Volpe, Thomas Felix Lüscher, Francesco Cosentino · 2012 · Circulation Research
57. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
    Udell, Jacob A, Cavender, Matthew A, Bhatt, Deepak L, Chatterjee, Saurav, Farkouh, Michael E, Scirica, Benjamin M · 2015 · The Lancet Diabetes &amp; Endocrinology
58. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline
    Peters, Anne L., Ahmann, Andrew J., Battelino, Tadej, Evert, Alison, Hirsch, Irl B., Murad, M. Hassan, Winter, William E., Wolpert, Howard · 2016 · The Journal of Clinical Endocrinology &amp; Metabolism
59. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary
    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John Dean Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan A. Fowler, Gary H. Friday et al. · 2011 · Catheterization and Cardiovascular Interventions
60. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
    Ashish M. Kamat, Thomas W. Flaig, H. Barton Grossman, Badrinath R. Konety, Donald L. Lamm, Michael A. O’Donnell, Edward Uchio, Jason Alexander Efstathiou, John Arthur Taylor · 2015 · Nature Reviews Urology
61. Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies
    Jennie H. Best, Byron J. Hoogwerf, William H. Herman, Elise M. Pelletier, Daniel B. Smith, Madé Wenten, Mohamed A. Hussein · 2010 · Diabetes Care
62. ESVM Guideline on peripheral arterial disease
    Ulrich Frank, Sigrid Nikol, J. J. F. Belch, Vinko Boc, Marianne Brodmann, P. Carpentier, Ali Chraim, Caitríona Canning, Evangelos P. Dimakakos, Anders Gottsäter et al. · 2019 · VASA
63. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
    Lee, Dustin M., Battson, Micah L., Jarrell, Dillon K., Hou, Shuofei, Ecton, Kayl E., Weir, Tiffany L., Gentile, Christopher L. · 2018 · Cardiovascular Diabetology
64. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
    The ORIGIN Trial Investigators, Mellbin, Linda G., Rydén, Lars, Riddle, Matthew C., Probstfield, Jeffrey, Rosenstock, Julio, Díaz, Rafael, Yusuf, Salim, Gerstein, Hertzel C. · 2013 · European Heart Journal
65. HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes
    Kasia J. Lipska, E. Margaret Warton, Elbert S. Huang, Howard H. Moffet, Silvio E. Inzucchi, Harlan M. Krumholz, Andrew John Karter · 2013 · Diabetes Care
66. Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes
    Pai‐Feng Hsu, Shih‐Hsien Sung, Hao‐Min Cheng, Jong Shiuan Yeh, Wen‐ling Liu, Wan‐Leong Chan, Chen‐Huan Chen, Pesus Chou, Shao‐Yuan Chuang · 2012 · Diabetes Care
67. Pharmacological treatment of hyperglycemia in type 2 diabetes
    Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees · 2021 · Journal of Clinical Investigation
68. Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: An umbrella review of systematic reviews and meta-analyses
    Timpel, Patrick, Oswald, Sarah, Schwarz, Peter E H, Harst, Lorenz · 2020 · Journal of Medical Internet Research
69. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, Prabhat Jha, Baiju R. Shah · 2022 · Nature Reviews Endocrinology
70. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
    for the ADVANCE Collaborative group, de Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D. E., Hackett, M. et al. · 2009 · Diabetologia
71. Roux-en-Y Gastric Bypass Surgery or Lifestyle With Intensive Medical Management in Patients With Type 2 Diabetes
    Florencia Halperin, Su-Ann Ding, Donald C. Simonson, Jennifer Panosian, ANN E. GOEBEL-FABBRI, Marlene Wewalka, Osama Hamdy, Martin J. Abrahamson, Kerri A. Clancy, Kathleen Foster et al. · 2014 · JAMA Surgery
72. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
    Greg L. Moneta · 2009 · Yearbook of Vascular Surgery
73. Epigenetic phenomena linked to diabetic complications
    Pirola, Luciano, Balcerczyk, Aneta, Okabe, Jun, El-Osta, Assam · 2010 · Nature Reviews Endocrinology
74. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
    Alexander J M Brown, Stephen J. Gandy, Rory J. McCrimmon, J. Graeme Houston, Allan D. Struthers, Chim Choy Lang · 2020 · European Heart Journal
75. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
    Wong, Muh Geot, Perkovic, Vlado, Chalmers, John, Woodward, Mark, Li, Qiang, Cooper, Mark E., Hamet, Pavel, Harrap, Stephen, Heller, Simon, MacMahon, Stephen et al. · 2016 · Diabetes Care
76. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests
    Dunn, Timothy C., Xu, Yongjin, Hayter, Gary, Ajjan, Ramzi A. · 2018 · Diabetes Research and Clinical Practice
77. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
    Rafael Simó, Cristina Hernández · 2015 · Progress in Retinal and Eye Research
78. Epidemiology in diabetes mellitus and cardiovascular disease
    Wenjun Fan · 2017 · Cardiovascular Endocrinology
79. Diabetes Mellitus Worsens Diastolic Left Ventricular Dysfunction in Aortic Stenosis Through Altered Myocardial Structure and Cardiomyocyte Stiffness
    Inês Falcão‐Pires, Nazha Hamdani, Attila Borbély, Cristina Gavina, Casper G. Schalkwijk, Jolanda van der Velden, Loek van Heerebeek, Ger J.M. Stienen, Hans W.M. Niessen, Adelino Ferreira Leite-Moreira et al. · 2011 · Circulation
80. Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
    Julio Rosenstock, Jane E.B. Reusch, Mark Bush, Fred Yang, Murray W Stewart, for the Albiglutide Study Group · 2009 · Diabetes Care
81. Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia—When Do the Risks of Diabetes Begin? A Consensus Statement From the American College of Endocrinology and the American Association of Clinical Endocrinologists*
    Alan J. Garber, Yehuda Handelsman, DANIEL F. EINHORN, Donald A. Bergman, Zachary T. Bloomgarden, Vivian Andrew Fonseca, William Timothy Garvey, James R. Gavin, George Grunberger, Edward S. Horton et al. · 2008 · Endocrine Practice
82. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
    Stephan D. Fihn, Julius M. Gardin, Jonathan Abrams, Kathleen Berra, James C. Blankenship, Apostolos P. Dallas, Pamela S. Douglas, JoAnne Micale Foody, Thomas C. Gerber, Alan L. Hinderliter et al. · 2012 · Journal of the American College of Cardiology
83. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Heidi Storgaard, Lise Lotte Gluud, Cathy Bennett, Magnus F.G. Grøndahl, Mikkel Christensen, Filip Krag Knop, Tina Vilsbøll · 2016 · PLoS ONE
84. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
    Publisher Chandrasekhara Rao Baru · 2014 · ADVANCED SCIENCES INDEX
85. Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?
    Greet Van den Berghe, Miet Schetz, Dirk Vlasselaers, Greet Hermans, Alexander P. Wilmer, Roger Bouillon, Dieter Mesotten · 2009 · The Journal of Clinical Endocrinology & Metabolism
86. Validation of the IMS CORE Diabetes Model
    Phil C. McEwan, VOLKER FOOS, James L. Palmer, Mark Lamotte, Adam Lloyd, David J.W. Grant · 2014 · Value in Health
87. Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
    Philip E. Cryer · 2014 · Diabetes
88. Epidemiology of polyneuropathy in diabetes and prediabetes
    Dan Ziegler, Νικόλαος Παπάνας, Aaron I. Vinik, Jonathan E. Shaw · 2014 · Handbook of clinical neurology
89. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes
    Lee, Alexandra K., Warren, Bethany, Lee, Clare J., McEvoy, John W., Matsushita, Kunihiro, Huang, Elbert S., Sharrett, A. Richey, Coresh, Josef, Selvin, Elizabeth · 2018 · Diabetes Care
90. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
91. Proteinuria: detection and role in native renal disease progression
    José Luis Górriz, Alberto Martínez‐Castelao · 2011 · Transplantation Reviews
92. Metformin: An Old Drug with New Applications
    Joseph Yi Zhou, Scott Massey, Darren T. Story, Lixin Li · 2018 · International Journal of Molecular Sciences
93. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    Holman, Rury R, Sourij, Harald, Califf, Robert M · 2014 · The Lancet
94. The interaction of chronic and acute glycemia with mortality in critically ill patients with diabetes*
    Moritoki Egi, Rinaldo Bellomo, Edward Stachowski, Craig French, Graeme K. Hart, Gopal Taori, Colin Hegarty, Michael Bailey · 2010 · Critical Care Medicine
95. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack
    Jesse Dawson, Yannick Béjot, Louisa Marguerite Christensen, Gian Marco De Marchis, Martin Dichgans, Guri Hagberg, Mirjam R. Heldner, Haralampos J. Milionis, Linxin Li, Francesca Romana Pezzella et al. · 2022 · European Stroke Journal
96. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
    Abraham Michael Lincoff, Jean‐Claude Tardif, Gregory G. Schwartz, Stephen James Nicholls, Lars Rydén, Bruce Charles Neal, Klas Malmberg, Hans Wedel, John B. Buse, Robert R. Henry et al. · 2014 · JAMA
97. Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
    Naifa Lamki Busaidy, Azeez Farooki, Afshin Dowlati, John Peter Perentesis, Janet Ellen Dancey, Laurence Austin Doyle, Joanna M. Brell, Lillian L. Siu · 2012 · Journal of Clinical Oncology
98. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies
    Silbert, Richard, Salcido-Montenegro, Alejandro, Rodriguez-Gutierrez, Rene, Katabi, Abdulrahman, McCoy, Rozalina G. · 2018 · Current Diabetes Reports
99. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis
    Khunti, Kamlesh, Seidu, Samuel, Kunutsor, Setor, Davies, Melanie · 2017 · Diabetes Care
100. Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture
     George Liang King, Kyoungmin Park, Qian Li · 2016 · Diabetes